TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04661930
Drug: TriCor® 145mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate; 145 mg daily (1/day); oral administration; 10 days
Study: NCT04749979
Drug: Agonist (decapeptyl )
Approvals — FDA: no, EMA: no, PMDA: no
Description: giving agonist
Study: NCT05332067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
Study: NCT06515652
Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparing allopathic and herbal group of drugs for metabolic syndrome
Study: NCT05633576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of placebo eye drops three times a day for four consecutive weeks.
Study: NCT05607979
Drug: Lavior Diabetic Wound Gel
Normalized name: hyaluronate Topical Gel [IPM Wound]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of hydrogel treatment for 60 days.
Study: NCT05913427
Drug: Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
Study: NCT05607979
Drug: Smith & Nephew Solosite Gel Hydrogel Wound Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of hydrogel treatment for 60 days.
Study: NCT06495307
Drug: rhPRG4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile isotonic aqueous solution containing rhPRG4 (450 µg/mL) for topical administration, 10 mM sodium phosphate, 150 mM sodium chloride \& 0.01% polysorbate 20 at pH 7.2. In all subjects, both eyes will be treated
Study: NCT05053087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline filled catheter
Study: NCT03306615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride Injection
Study: NCT06376604
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of standard chemotherapy for the gynecologic malignancy.
Study: NCT05014594
Drug: Placebo of dapaglifozin along with standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy will include dietary restriction of sodium, treatment with diuretics, repeated LVP as needed and other supportive care. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study: NCT04842292
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized heparin 25,000 units every 6 hours
Study: NCT04842292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% every 6 hours
Study: NCT05618457
Drug: Aminoglycoside dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients may have the aminoglycoside dose adjusted based on pathogen MIC, to attain the PK/PD target of Cam/MIC\~10 (8-12)
Study: NCT06520176
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1\~Day 2: 1～2g/m\^2
Study: NCT05604989
Drug: Probiotic Combination Cap/Tab
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Perfect Probiotics® capsule will be given as an intervention, which is composed of mostly Lactobacillus acidophilus \& Bifidobacterium lactis.
Study: NCT06430047
Drug: EsoDuo® Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05622240
Drug: 99mTc-MIRC213
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-MIRC213 were intravenous injected into the patients before the wholebody and SPECT/CT scans
Study: NCT05022771
Drug: PMG1015 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 of PMG1015
Study: NCT05022771
Drug: PMG1015 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 2 of PMG1015
Study: NCT05022771
Drug: PMG1015 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 3 of PMG1015
Study: NCT05022771
Drug: PMG1015 Dose 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 4 of PMG1015
Study: NCT05022771
Drug: PMG1015 Dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 5 of PMG1015
Study: NCT05022771
Drug: PMG1015 Dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 6 of PMG1015
Study: NCT05022771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT05022771
Drug: PMG1015 Dose 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 7 of PMG1015
Study: NCT06553456
Drug: Recombinant Human Serum Albumin
Normalized name: RECOMBINANT HUMAN SERUM ALBUMIN ORYZA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental drug was administered at a dose of 20 g/ day for 7 days.
Study: NCT06241599
Drug: GP/PFLL+AK104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks).
Study: NCT06241599
Drug: GP/PFLL+placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks).
Study: NCT05582811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05201859
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An oral anticancer agent that can be converted into 5-Fu in vivo.
Study: NCT05861674
Drug: TAF
Normalized name: Altafed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
Study: NCT05060666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An analogous number of tablets is administered for placebo:~* 5 tablets for 40-60 kg~* 6 tablets for 60-80 kg~* 8 tablets for \> 80 kg~The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin.
Study: NCT04964219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After anesthesia induction, a bolus of placebo (normal saline) in the same volume is injected intravenously about 30 min before incision; this is followed by a continuous infusion of placebo at the same rate until 1 hour before the end of surgery.~After surgery, patient-controlled analgesia is provided. The pump is established with placebo, dexmedetomidine 100 microgram and sufentanil 100 microgram, diluted with normal saline to 100 ml. The pump is programmed to deliver 2-ml boluses with a background infusion rate at 1 ml /h and a 10-min lockout interval.
Study: NCT05753878
Drug: HH-120 nasal spray, Part A cohort 2-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of HH-120 nasal spray.
Study: NCT05753878
Drug: HH-120 nasal spray, Part A cohort 8-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of HH-120 nasal spray.
Study: NCT05753878
Drug: HH-120 nasal spray, Part B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HH-120 nasal spray, 10 times daily for 7 consecutive days.
Study: NCT05769842
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dose as propofol.
Study: NCT04702555
Drug: VTS-K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
Study: NCT05203419
Drug: MHS552
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Study: NCT05203419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once weekly as subcutaneous injection for 4 weeks (Part A) or 12 weeks (Part B)
Study: NCT05291598
Drug: IV meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered meloxicam 30 mg IV push pre-operatively.
Study: NCT05291598
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be treated with ketorolac 15 mg IV push intra-operatively, followed by 15 mg IV push every 6 hours scheduled for 2 doses.
Study: NCT06448312
Drug: SKB264
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT05504148
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take placebo piece during for 8 days during each chemotherapy (started on the 1st day before radiotherapy/chemotherapy), 4 tablets/time, 3 times a day
Study: NCT06242067
Drug: Trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
Study: NCT06046495
Drug: PLB1004
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1004 will be orally self-administered by the patient as a mono-therapy.
Study: NCT05132699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inert strawberry flavored oral solution, taken as a 2.5ml dose twice a day
Study: NCT06451211
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2500 mg will be administered orally on day 1-14 of each cycle in all participants
Study: NCT06111261
Drug: Balanced crystalloid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced crystalloid solution
Study: NCT05725057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to this arm will receive placebo treatment for 28 days with a 30 day safety follow-up period.
Study: NCT04575857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control arm will receive a pill packet with placebo x 18 months.
Study: NCT05800444
Drug: BAY3283142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration as tablet.
Study: NCT06072001
Drug: Adezunap (AP707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day or a maximum daily dose of 17,6mg THC distributed over 4 daily intakes.
Study: NCT06072001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual spray with maximum application of 16 actuations per day distributed over 4 daily intakes.
Study: NCT06552598
Drug: KD01(the recombinant oncolytic adenovirus)
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ia PART 1 (Dose Escalation Phase with Monotherapy): Subjects in each dose group will continue to undergo a 21-day assessment for Dose-Limiting Toxicity (DLT) after completing the first cycle of treatment (D1-5), totaling 26 days starting from D1.~Phase Ib PART 2 (Dose Expansion Phase with Monotherapy): Subjects will receive intratumoral injections, starting on D1. Further treatment will continue based on the patient's willingness, with a maximum of 5 administrations. The final administration will be followed by surgery 7-14 days later, until the patient is discharged.
Study: NCT06360874
Drug: MAD_ND003_Dose 1
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study: NCT06360874
Drug: MAD_ND003_Dose 2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study: NCT06360874
Drug: MAD_ND003_Dose 3
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will orally administrated the ND-003 tablets once a day , in which the dose will be determined based on the results of SAD.
Study: NCT06360874
Drug: MAD_ placebo_Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will orally administrated the placebo tablets matching to the MAD_ND003_Dose 3
Study: NCT06360874
Drug: Food effect_Cohort 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly orally administrated ND-003 tablets in fast state and then in fed state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Study: NCT06360874
Drug: Food effect_Cohort 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly orally administrated ND-003 tablets in fed state and then in fast state after a 7-day washout period. Wherein, the dose will be determined based on the results of SAD and MAD.
Study: NCT05496491
Drug: Consolidation Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX (Capecitabine bid1000 mg/m2 and Oxaliplatin 130 mg/m2, day 1, every 3 weeks) or alternatively FOLFOX
Study: NCT05955586
Drug: SPR720
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR720 1000 mg (250 mg\*4 capsules) will be administered orally.
Study: NCT00005117
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06065267
Drug: sequential
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week
Study: NCT04901065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
Study: NCT05726903
Drug: Depo-subQ Provera Injectable Product
Normalized name: depo-subQ provera Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Injection at Home
Study: NCT05909215
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20mL will be given intravenously through a syringe pump over 10 minutes
Study: NCT05078463
Drug: 0.5 Finger Tip Unit (FTU) EMLA (30-minute application time)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 Finger Tip Unit (FTU) EMLA applied for 30 minutes on the dorsal surface of the IV cannulated hand for blood transfusion
Study: NCT05480293
Drug: SCT510A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT510A，1.25mg,IVT
Study: NCT04860661
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml normal saline
Study: NCT05364905
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Study: NCT05674045
Drug: EG017 3mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG017 3mg/day Oral administration for 12 weeks, once daily
Study: NCT05674045
Drug: EG017 6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG017 6mg/day Oral administration for 12 weeks, once daily
Study: NCT05475821
Drug: Placebo for ABBV-990
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05943327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT04699604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06291103
Drug: Conversion to Belatacep
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI will be tapered within 3 months: 75 % of initial dose on the first month, 50 % on the second month, 25 % on the third month, and stopped and a conversion to Belatacept will be performed. It will be administered (6mg/kg) every 2W for the first 2 months and then every month until kidney graft survival.
Study: NCT06416956
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will record infant\&#39;s brain activity and vital signs when caffeine dose is changed or caffeine treatment is stopped. The decision to change dose/stop treatment will be made by the clinical team as part of routine care. No changes in caffeine treatment will be carried out solely for research purposes.
Study: NCT05012319
Drug: to be given as a treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide Nasal Spray Enovid
Study: NCT05518734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-708 for IV administration.
Study: NCT04975971
Drug: Dextenza 0.4Mg Ophthalmic Insert
Normalized name: Dextenza 0.4mg Ophthalmic Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.
Study: NCT06121934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: visually matched placebo 2 capsule t.i.d for 5 days
Study: NCT05388435
Drug: SKL27969
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
Study: NCT04304755
Drug: Zoledronic Acid 5 MG in 5 ML Injection
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid
Study: NCT04967508
Drug: Stelara® (Ustekinumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.
Study: NCT06100432
Drug: DLBS5055 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x1 caplet
Study: NCT06100432
Drug: Placebo DLBS5055
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x1 caplet
Study: NCT06100432
Drug: Placebo Multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x2 caplets
Study: NCT05329155
Drug: Heparin Sodium Injection
Normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin Sodium Injection (100U/Kg body weight)
Study: NCT04975269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06113445
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, Tablet
Study: NCT05938699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX 0.1% vs Placebo
Study: NCT06274489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching film-coated placebo tablets, containing only excipients
Study: NCT05895513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive Comparator
Study: NCT05060991
Drug: Reduction in antimetabolite immunosuppression
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
Study: NCT05536414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule
Study: NCT04710524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for 13 weeks
Study: NCT04710524
Drug: FM101 150 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM101 (150 mg) BID for 13 weeks
Study: NCT04710524
Drug: FM101 300 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: FM101 (300 mg) BID for 13 weeks
Study: NCT06770582
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06161025
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD will be administered as an IV infusion
Study: NCT04647227
Drug: coagulation factor VIIa [recombinant]-jncw
Approvals — FDA: no, EMA: no, PMDA: no
Description: a transgenically produced, activated, recombinant, human factor VII (rhFVIIa) protein with the brand name of SEVENFACT®. This protein is a clotting factor in the coagulation cascade that is produced in and purified from the milk of transgenic rabbits. SEVENFACT is approved for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.
Study: NCT06203912
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06531395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile preservative-free solution
Study: NCT06205329
Drug: WPV01 Dose 1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPV01 Dose 1-4 or Placebo on day 1
Study: NCT06205329
Drug: WPV01 Dose 9-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPV01 Dose 9-12 or Placebo from day 1 to day 6